23382-09-4

Basic information

• Product Name: silicon dioxide hydrate
• Synonyms: silicon dioxide hydrate
• CAS NO: 23382-09-4
• Molecular Weight: 78.0996
• Mol File: 23382-09-4.mol

Chemical Properties

• CAS DataBase Reference: silicon dioxide hydrate(CAS DataBase Reference)
• NIST Chemistry Reference: silicon dioxide hydrate(23382-09-4)
• EPA Substance Registry System: silicon dioxide hydrate(23382-09-4)

Safety Data

• Hazardous Substances Data: 23382-09-4(Hazardous Substances Data)

Downstream Products

• 301526-80-7 4chloro-5-(4chlorophenoxy)-2-(diisopropylaminomethyleneamino)-pyrimidine 
• 156787-33-6 methyl 3,5-dimethyl-4-<<3-(3-methyl-5-isoxazolyl)propyl>oxy>benzoate 
• 126632-44-8 Ethyl 4-[(5-cyano-6-ethoxy-6-oxohexyl)tosylamino]benzoate 
• 79276-58-7 8-(2-oxopyrrolidin-1-yl)quinoline 
• 28981-97-7 alprazolam 
• 164332-88-1 tert-butyl N-[2-(2-bromoethoxy)ethyl]carbamate 
• 136080-53-0 1'-benzoyl-6-nitrospiro[chroman-2,4'-piperidin]-4-one 
• 136080-54-1 6-amino-1'-benzoyl-3,4-dihydro-spiro[(2H)-1-benzopyran-2-4'-piperidine]-4-one 
• 168267-01-4 2-hydroxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzaldehyde 
• 161167-79-9 cis-3-amino-2-phenyl-piperidine 
• 114151-18-7 N-[3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-propyl]hydroxyl-amine 
• 85397-18-8 2-(3-fluoro-4-nitrophenyl)propanenitrile 
• 173900-19-1 3-bromomethyl-5-[3-(tert-butyldiphenylsilyloxy)propyl]isoxazole 
• 93148-78-8 ethyl 4-(2-Piperidinylethoxy)benzoate 

Relevant articles and documents

THERAPEUTIC COMPOSITIONS CONTAINING GLUTATHIONE ANALOGS

Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.

Methods for isolating nucleic acids from biological and cellular materials

Methods of isolating nucleic acids from samples of biological or cellular material are disclosed which use solid phase binding materials and which avoid the use of any lysis solution or coating. The use of the solid phase binding materials unexpectedly allow the nucleic acid content of cells to be freed and captured directly and in one step. The new methods represent a significant simplification over existing methods. Nucleic acids can be captured and released in a form suitable for downstream processing in under five minutes. Preferred solid phase materials for use with the methods and compositions of the invention comprise a quaternary onium nucleic acid binding portion.

5,6,7-trinor-4,8-inter-m-phenylene PGI2, derivative and drugs containing the same

The present invention provides novel PGI2derivatives and an anti Helicobacter agent, a platelet function potentiating agent or a cervical ripening agent containing any of the derivatives.

Substituted gamma-phenyl-delta-lactams and uses related thereto

gamma-Phenyl-substituted Delta-lactams are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.

Modulators of LXR

Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors. In certain embodiments, the compounds are N-substituted pyridones.

Therapeutic compositions containing glutathione analogs

Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.

3-nitrogen-6,7-dioxygen steroids and uses related thereto

A compound of the formula and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein, independently at each occurrence: R1 and R2 are selected from hydrogen, oxygen so as to form nitro or oxime, amino, sulfate, and sulfonic acid, and organic groups having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen, phosphorous, silicon, and sulfur, where R1 and R2 may, together with the N to which they are both bonded, form a heterocyclic structure that may be part of an organic group having 1-30 carbons and optionally containing 1-6 heteroatoms selected from nitrogen, oxygen and silicon, and where R1 may be a 2, or 3 atom chain to numeral 2 so that —N—R1— forms part of a fused bicyclic structure to ring A; R3 and R4 are selected from direct bonds to 6 and 7 respectively so as to form carbonyl groups, hydrogen, or a protecting group such that R3 and/or R4 is part of hydroxyl or carbonyl protecting group; numerals 1 through 17 each represent a carbon having substitution as described. The compounds may be formulated into pharmaceutical compositions, and used in the treatment and/or prevention of various conditions, including inflammation, asthma, an allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, solid tumors, AIDS, ischemia, and cardiac arrhythmias.

Method for lowering blood alcohol concentration by administering an extract of Rhus verniciflua

A method for lowering blood alcohol concentration by administering an extract ofRhus vernicifluato human, thereby preventing or treating a disease state caused by intake of an alcohol.

Synthesis of low-fluoride organic compounds

Organic compounds, e.g. fluorinated organic compounds such as fluorinated carboxylic acids or fluorinated carboxylic acid chlorides, may contain small amounts of carboxylic acid fluorides, hydrogen fluoride or hydrolyzable fluoride, which during the preparation of derivatives of the fluorinated organic compounds, for example by esterification, may yield corrosive fluorides or hydrogen fluoride. The invention is a method for the synthesis and/or purification of preferably fluorinated organic compounds such as carboxylic acids, carboxylic acid chlorides and derivatives such as esters thereof, starting from corresponding carboxylic acid chlorides containing acid fluorides or hydrolyzable fluoride, and alcohols under the catalytic action of “onium” salts of carboxylic acids, to obtain products which have a low fluoride content. Alternatively, an inorganic oxide adsorbent is utilized. The method is especially suitable for the synthesis of esters of trifluoroacetic acid, chlorodifluoroacetic acid, trifluoroacetoacetic acid and/or difluoroacetoacetic acid.

Nocathiacin antibiotics

Novel thiazolyl peptide antibiotic compounds, including nocathiacin I, II and III, are disclosed. Also, novel microorganism ATCC-202099 is disclosed.